Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OCULUS INC.
Report date June 10, 2020 · Filed June 11, 2020
Section 16 reporting ended · disclosed 2020-06-11. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2020 Filed Jun 9, 2020 19:11 UTC | OCULUS INC. OVTZ · Entity 8451 | PurchaseCommon shares | 666,667 | $0.15 | $100,000.05 |
DisclosureSEC source: 0001437749-20-012724 · rdgdoc.xml · nonDerivative · entry 1 Nichols Shawn Norman · CIK 0001799642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980,702 F1 · kind: The shares were acquired on June 5, 2020 pursuant to non-brokered private placement financing at a price of CAD $0.15 per shared converted to USD $0.112 F2 · price: Expressed in Canadian dollars. Read SEC document |
| April 27, 2020 Filed Apr 27, 2020 23:28 UTC | OCULUS INC. OVTZ · Entity 8451 | GrantCommon shares | 31,100 | $0.18 | $5,473.60 |
DisclosureSEC source: 0001437749-20-008606 · rdgdoc.xml · nonDerivative · entry 1 Nichols Shawn Norman · CIK 0001799642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,314,035 F1 · price: The shares were acquired on April 21, 2020 in the open market at a price of CAD $0.245 converted to USD $0.176 Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:32 UTC | OCULUS INC. OVTZ · Entity 8451 | GrantCommon shares | 65,000 | $0.15 | $9,899.50 |
DisclosureSEC source: 0001437749-20-008222 · rdgdoc.xml · nonDerivative · entry 1 Nichols Shawn Norman · CIK 0001799642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,935 F1 · price: The shares were acquired on April 21, 2020 in the open market at a price of CAD $0.216 converted to USD $0.1523 Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:16 UTC | OCULUS INC. OVTZ · Entity 8451 | GrantCommon shares | 100,000 | $0.14 | $14,000.00 |
DisclosureSEC source: 0001437749-20-004022 · rdgdoc.xml · nonDerivative · entry 1 Nichols Shawn Norman · CIK 0001799642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,935 F1 · price: The shares were acquired on February 26, 2020 in the open market at a price of CAD $0.185 converted to USD $0.14 Read SEC document |
| January 29, 2020 Filed Feb 3, 2020 18:26 UTC | OCULUS INC. OVTZ · Entity 8451 | GrantCommon shares | 500,000 | $0.11 | $57,000.00 |
DisclosureSEC source: 0001437749-20-001535 · rdgdoc.xml · nonDerivative · entry 1 Nichols Shawn Norman · CIK 0001799642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,117,935 F1 · price: The shares were acquired on January 29, 2020 in the open market at a price of CAD $0.15 converted to USD $0.114 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.